Artisan Global Discovery Fund on Twist Bioscience Corporation
Thesis
Twist has a proprietary silicon-based DNA writing platform serving drug discovery, diagnostics and related markets. Revenue grew 23% year over year, exceeding expectations as DNA synthesis and protein solutions strengthened. Partnerships and evaluation work involving Amazon Bio Discovery and Anthropic point to growing relevance in AI-enabled drug discovery. The manager retained exposure but trimmed after the shares appreciated strongly.
“Revenue grew 23% year over year, exceeding expectations”
Key risks
- Recent share-price appreciation may have pulled forward part of the investment return.
- The growth thesis depends on sustained demand for DNA synthesis, protein solutions and newer AI-enabled discovery applications.